Alnylam, Merck dump RNAi deal

A little more than a year after revising their RNAi development deal to include $120 million in milestone payments, Alnylam says it is fundamentally in its best interests to terminate the pact with Merck. After they amended that deal last summer, Merck bought Sirna Therapeutics for $1.1 billion, which put Merck directly into the RNAi space. Alnylam has other partnerships still in the works with Novartis and Biogen Idec, and it recently formed a new company with Isis Pharmaceuticals to focus on developing new drugs based on micro-RNA. Investors and analysts alike were quick to applaud the move, sending Alnylam's shares up sharply.

- check out Alnylam's release on the decision
- read the report from MassHighTech

Related Articles:
Merck, Alnylam recalibrate development pact. Report
Roche harnesses Alnylam's RNAi tech in $1B deal. Report
RNAi leaders Isis, Alnylam form new company. Report
A billion-dollar lesson in RNAi economics. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.